TY  - JOUR
AU  - Farkas, Gyula
AU  - Nagy, Sándor
AU  - Dévay, Attila
AU  - Széchenyi, Aleksandar
AU  - Pál, Szilárd
TI  - Real-Time Cone-Growth Model for Determination of Pharmaceutical Powder Flow Properties
JF  - PHARMACEUTICS
J2  - PHARMACEUTICS
VL  - 16
PY  - 2024
IS  - 3
PG  - 18
SN  - 1999-4923
DO  - 10.3390/pharmaceutics16030405
UR  - https://m2.mtmt.hu/api/publication/34763930
ID  - 34763930
N1  - Export Date: 12 April 2024            
            Correspondence Address: Pál, S.; Institute of Pharmaceutical Technology and Biopharmacy, Rókus Str. 2, Hungary; email: szilard.pal@aok.pte.hu
AB  - The flow properties of pellets or granules are crucial for further processing drug dosage forms. Optimal compression or filling of multiparticulate dosage forms into capsules is influenced by forces between discrete particles, which could be partially characterized by flow properties. Several techniques have been developed to examine flowability, including static and dynamic methods applying empirical studies and up-to-date chaos theory; however, the newest methods seem only to be powerful with the supplementation of empirical principles. Our experiments try to refine both the technique of analysis and the methods, by finding new, alternative ways. Our approach to the flowability measurements was to set up a dynamic time-dependent model that combined empirical observations and chaos theory on a geometrical basis, thus finding new characteristics regarding the flow properties of pellets and granules that could be relevant for drug developers. Our findings indicate that sphericity and particle size are the most significant factors influencing the flowability of pharmaceutical multiparticular preparations. Furthermore, this study confirms that integrating chaos theory and empirical observations in a time-dependent dynamic model provides a comprehensive understanding of particle flow behavior, pivotal for optimizing manufacturing processes.
LA  - English
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Helyes, Zsuzsanna
AU  - Horvath, Adam Istvan
AU  - Szentes, Nikolett
AU  - Tekus, Valeria
AU  - Kálai, Tamás
AU  - Pál, Szilárd
AU  - Szoke, Eva
AU  - Matyus, Peter
TI  - Development of a novel multi-target drug candidate for neuropathic pain: preclinical and phase I clinical studies
JF  - BRITISH JOURNAL OF PHARMACOLOGY
J2  - BR J PHARMACOL
VL  - 180
PY  - 2023
SP  - 433
EP  - 434
PG  - 2
SN  - 0007-1188
UR  - https://m2.mtmt.hu/api/publication/34212245
ID  - 34212245
LA  - English
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Varga, Adorján
AU  - Makszin, Lilla
AU  - Bufa, Anita
AU  - Sipos, Dávid
AU  - Kása, Péter
AU  - Pál, Szilárd
AU  - Rosenstiel, Philip
AU  - Sommer, Felix
AU  - Kocsis, Béla
AU  - Péterfi, Zoltán
TI  - Efficacy of lyophilised bacteria-rich faecal sediment and supernatant with reduced bacterial count for treating patients with Clostridioides difficile Infection – A novel method for capsule faecal microbiota transfer
JF  - FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
J2  - FRONT CELL INFECT MI
VL  - 13
PY  - 2023
PG  - 15
SN  - 2235-2988
DO  - 10.3389/fcimb.2023.1041384
UR  - https://m2.mtmt.hu/api/publication/33588242
ID  - 33588242
N1  - * Megosztott szerzőség
LA  - English
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Vörös-Horváth, Barbara
AU  - Zivkovic, Pavo
AU  - Bánfai, Krisztina
AU  - Bovári-Biri, Judit
AU  - Pongrácz, Judit
AU  - Bálint, Gábor
AU  - Pál, Szilárd
AU  - Széchenyi, Aleksandar
TI  - Preparation and Characterization of ACE2 Receptor Inhibitor-Loaded Chitosan Hydrogels for Nasal Formulation to Reduce the Risk of COVID-19 Viral Infection
JF  - ACS OMEGA
J2  - ACS OMEGA
VL  - 7
PY  - 2022
IS  - 4
SP  - 3240
EP  - 3253
PG  - 14
SN  - 2470-1343
DO  - 10.1021/acsomega.1c05149
UR  - https://m2.mtmt.hu/api/publication/32623813
ID  - 32623813
AB  - The COVID-19 virus is spread by pulmonary droplets. Its high infectivity is caused by the high-affinity binding of the viral spike protein to the ACE2 receptors on the surface of respiratory epithelial cell membranes. The proper hydration of nasal mucosa plays an essential role in defense of bacterial and viral infections. Therefore, a nasal formulation, which can moisture the nasal mucosa and contains the ACE2 receptor inhibitor, can reduce the risk of COVID-19 infection. This article presents a systematic study of the preparation of chitosan hydrogels with dicarboxylic acids (malic and glutaric acid) and their detailed characterization (Fourier transform infrared spectroscopy, deter-mination of cross-linking efficiency, rheological studies, thermal analysis, and swelling kinetics). The results confirm that chemically cross-linked chitosan hydrogels can be synthesized using malic or glutaric acid without additives or catalysts. The adsorption capacity of hydrogels for three different ACE2 inhibitors, as APIs, has also been investigated. The API content of hydrogels and their mucoadhesive property can provide an excellent basis to use the hydrogels for the development of a nasal formulation in order to reduce the risk of SARS-CoV 2 infection.
LA  - English
DB  - MTMT
ER  - 

TY  - CHAP
AU  - Bakó, Csongor
AU  - Balázs, Viktória Lilla
AU  - Takács, Gyöngyi
AU  - Pallos, József Péter
AU  - Pál, Szilárd
AU  - Kocsis, Béla
AU  - Pethő, Dóra
AU  - Horváth, Györgyi
TI  - Muskotályzsálya (Salvia sclarea L.) szuperkritikus fluid extraktumok biológiai aktivitásának optimalizálása válaszfelület modellezés segítségével
T2  - METT25 a Magyar Elválasztástudományi Társaság jubileumi konferenciája
PB  - Magyar Elválasztástudományi Társaság
CY  - Pécs
SN  - 9786155270666
PY  - 2021
UR  - https://m2.mtmt.hu/api/publication/32474355
ID  - 32474355
LA  - Hungarian
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Bakó, Csongor
AU  - Balázs, Viktória Lilla
AU  - Takács, Gyöngyi
AU  - Pallos, József Péter
AU  - Pál, Szilárd
AU  - Kocsis, Béla
AU  - Pethő, Dóra
AU  - Horváth, Györgyi
TI  - Combination of Analytical and Statistical Methods in Order to Optimize Antibacterial Activity of Clary Sage Supercritical Fluid Extracts
JF  - MOLECULES
J2  - MOLECULES
VL  - 26
PY  - 2021
IS  - 21
PG  - 15
SN  - 1420-3049
DO  - 10.3390/molecules26216449
UR  - https://m2.mtmt.hu/api/publication/32471114
ID  - 32471114
LA  - English
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Horváth, Ádám István
AU  - Szentes, Nikolett
AU  - Tékus, Valéria
AU  - Payrits, Maja
AU  - Szőke, Éva
AU  - Pótóné Oláh, Emőke
AU  - Garami, András
AU  - Fliszár-Nyúl, Eszter
AU  - Poór, Miklós
AU  - Pápayné Sár, Cecília
AU  - Kálai, Tamás
AU  - Pál, Szilárd
AU  - Percze, Krisztina
AU  - Nagyné Scholz, Éva
AU  - Mészáros, Tamás
AU  - Tóth, Blanka
AU  - Mátyus, Péter
AU  - Helyes, Zsuzsanna
TI  - Proof-of-Concept for the Analgesic Effect and Thermoregulatory Safety of Orally Administered Multi-Target Compound SZV 1287 in Mice: A Novel Drug Candidate for Neuropathic Pain
JF  - BIOMEDICINES
J2  - BIOMEDICINES
VL  - 9
PY  - 2021
IS  - 7
PG  - 18
SN  - 2227-9059
DO  - 10.3390/biomedicines9070749
UR  - https://m2.mtmt.hu/api/publication/32084429
ID  - 32084429
LA  - English
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Salem, Ala'
AU  - Hagymási, A.
AU  - Vörös-Horváth, Barbara
AU  - Šafarik, T.
AU  - Balić, T.
AU  - Szabó, Péter
AU  - Gősi, F.
AU  - Nagy, Sándor
AU  - Pál, Szilárd
AU  - Kunsági-Máté, Sándor
AU  - Széchenyi, Aleksandar
TI  - Solvent dependent 4-aminosalicylic acid-sulfamethazine co-crystal polymorph control
JF  - EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
J2  - EUR J PHARM SCI
VL  - 156
PY  - 2021
PG  - 7
SN  - 0928-0987
DO  - 10.1016/j.ejps.2020.105599
UR  - https://m2.mtmt.hu/api/publication/31646675
ID  - 31646675
LA  - English
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Salem, Ala'
AU  - Takácsi-Nagy, Anna Erzsébet
AU  - Nagy, Sándor
AU  - Hagymási, Alexandra
AU  - Gősi, Fruzsina
AU  - Vörös-Horváth, Barbara
AU  - Balić, Tomislav
AU  - Pál, Szilárd
AU  - Széchenyi, Aleksandar
TI  - Synthesis and Characterization of Nano-Sized 4-Aminosalicylic Acid-Sulfamethazine Cocrystals
JF  - PHARMACEUTICS
J2  - PHARMACEUTICS
VL  - 13
PY  - 2021
IS  - 2
PG  - 13
SN  - 1999-4923
DO  - 10.3390/pharmaceutics13020277
UR  - https://m2.mtmt.hu/api/publication/31905073
ID  - 31905073
AB  - Drug-drug cocrystals are formulated to produce combined medication, not just to modulate active pharmaceutical ingredient (API) properties. Nano-crystals adjust the pharmacokinetic properties and enhance the dissolution of APIs. Nano-cocrystals seem to enhance API properties by combining the benefits of both technologies. Despite the promising opportunities of nano-sized cocrystals, the research at the interface of nano-technology and cocrystals has, however, been described to be in its infancy. In this study, high-pressure homogenization (HPH) and high-power ultrasound were used to prepare nano-sized cocrystals of 4-aminosalysilic acid and sulfamethazine in order to establish differences between the two methods in terms of cocrystal size, morphology, polymorphic form, and dissolution rate enhancement. It was found that both methods resulted in the formation of form I cocrystals with a high degree of crystallinity. HPH yielded nano-sized cocrystals, while those prepared by high-power ultrasound were in the micro-size range. Furthermore, HPH produced smaller-size cocrystals with a narrow size distribution when a higher pressure was used. Cocrystals appeared to be needle-like when prepared by HPH compared to those prepared by high-power ultrasound, which had a different morphology. The highest dissolution enhancement was observed in cocrystals prepared by HPH; however, both micro- and nano-sized cocrystals enhanced the dissolution of sulfamethazine.
LA  - English
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Varga, Adorján
AU  - Kocsis, Béla
AU  - Sipos, Dávid
AU  - Kása, Péter
AU  - Vigvári, Szabolcs József
AU  - Pál, Szilárd
AU  - Dembrovszky, Fanni
AU  - Borbásné Farkas, Kornélia
AU  - Péterfi, Zoltán
TI  - How to Apply FMT More Effectively, Conveniently and Flexible – A Comparison of FMT Methods
JF  - FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
J2  - FRONT CELL INFECT MI
VL  - 11
PY  - 2021
PG  - 11
SN  - 2235-2988
DO  - 10.3389/fcimb.2021.657320
UR  - https://m2.mtmt.hu/api/publication/32056248
ID  - 32056248
N1  - Department of Medical Microbiology and Immunology, University of Pécs Clinical Centre, Pécs, Hungary            
            Department of Internal Medicine – Department of Infectology, University of Pécs Clinical Centre, Pécs, Hungary            
            Institute of Pharmaceutical Technology and Biopharmacy, University of Pécs, Faculty of Pharmacy, Pécs, Hungary            
            Institute for Translational Medicine, University of Pécs Medical School, Pécs, Hungary            
            Institute of Bioanalysis, University of Pécs Medical School, Pécs, Hungary            
            Cited By :17            
            Export Date: 23 April 2024            
            Correspondence Address: Varga, A.; Department of Medical Microbiology and Immunology, Hungary
LA  - English
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Lendvai, B.
AU  - Nmar, F.
AU  - Kocsis, Béla
AU  - Horváth, Györgyi
AU  - Pál, Szilárd
AU  - Takácsi-Nagy, Anna Erzsébet
TI  - The development of a semi-solid formulation containing natural extracts as a hand-sanitizer preparation
JF  - ACTA PHARMACEUTICA HUNGARICA
J2  - ACTA PHARM HUNG
VL  - 90
PY  - 2020
IS  - 2-3
SP  - 127
EP  - 128
PG  - 2
SN  - 0001-6659
UR  - https://m2.mtmt.hu/api/publication/31613499
ID  - 31613499
LA  - English
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Széchenyi, Aleksandar
AU  - Vörös-Horváth, Barbara
AU  - Nagy, Sándor
AU  - Das, S.
AU  - Kőszegi, Tamás
AU  - Horváth, Györgyi
AU  - Balázs, Viktória Lilla
AU  - Varga, A.
AU  - Kocsis, Béla
AU  - Pál, Szilárd
TI  - Targeted delivery of essential oils for pharmaceutical applications
JF  - ACTA PHARMACEUTICA HUNGARICA
J2  - ACTA PHARM HUNG
VL  - 90
PY  - 2020
IS  - 2-3
SP  - 76
EP  - 76
PG  - 1
SN  - 0001-6659
UR  - https://m2.mtmt.hu/api/publication/31613161
ID  - 31613161
LA  - English
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Takácsi-Nagy, Anna Erzsébet
AU  - Székely, A.
AU  - Pál, Szilárd
TI  - The development of a semi-solid formulation containing cinnamon essential oil as a handsanitizer preparation
JF  - ACTA PHARMACEUTICA HUNGARICA
J2  - ACTA PHARM HUNG
VL  - 90
PY  - 2020
IS  - 2-3
SP  - 144
EP  - 144
PG  - 1
SN  - 0001-6659
UR  - https://m2.mtmt.hu/api/publication/31613591
ID  - 31613591
LA  - English
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Vörös-Horváth, Barbara
AU  - Nagy, Sándor
AU  - Das, Sourav
AU  - Kőszegi, Tamás
AU  - Pál, Szilárd
AU  - Széchenyi, Aleksandar
TI  - Application of nanotechnology in formulation of tioconazole and tea tree essential oil for onychomycosis topical treatment
JF  - ACTA PHARMACEUTICA HUNGARICA
J2  - ACTA PHARM HUNG
VL  - 90
PY  - 2020
IS  - 2-3
SP  - 150
EP  - 150
PG  - 1
SN  - 0001-6659
UR  - https://m2.mtmt.hu/api/publication/31613607
ID  - 31613607
LA  - English
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Vörös-Horváth, Barbara
AU  - Das, Sourav
AU  - Salem, Ala'
AU  - Nagy, Sándor
AU  - Böszörményi, Andrea
AU  - Kőszegi, Tamás
AU  - Pál, Szilárd
AU  - Széchenyi, Aleksandar
TI  - Formulation of Tioconazole and Melaleuca alternifolia Essential Oil Pickering Emulsions for Onychomycosis Topical Treatment
JF  - MOLECULES
J2  - MOLECULES
VL  - 25
PY  - 2020
IS  - 23
PG  - 17
SN  - 1420-3049
DO  - 10.3390/molecules25235544
UR  - https://m2.mtmt.hu/api/publication/31677449
ID  - 31677449
N1  - * Megosztott szerzőség
LA  - English
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Elhusseiny, Mohamed Mahmoud Abdelwahab
AU  - Rapp, Judit
AU  - Feller, Diána
AU  - Csöngei, Veronika
AU  - Pál, Szilárd
AU  - Bartis, Domokos Gergely
AU  - Thickett, David R
AU  - Pongrácz, Judit
TI  - Wnt signaling regulates trans-differentiation of stem cell like type 2 alveolar epithelial cells to type 1 epithelial cells
JF  - RESPIRATORY RESEARCH
J2  - RESP RES
VL  - 20
PY  - 2019
IS  - 1
PG  - 9
SN  - 1465-9921
DO  - 10.1186/s12931-019-1176-x
UR  - https://m2.mtmt.hu/api/publication/30792976
ID  - 30792976
N1  - * Megosztott szerzőség
AB  - Type 2 alveolar epithelial cells (AT2s) behave as stem cells and show clonal proliferation upon alveolar injury followed by trans-differentiation (TD) into Type 1 alveolar epithelial cells (AT1s). In the present study we identified signaling pathways involved in the physiological AT2-to-AT1 TD process.AT2 cells can be isolated from human lungs and cultured in vitro where they undergo TD into AT1s. In the present study we identified signaling pathways involved in the physiological AT2-to-AT1 TD process using Affymetrix microarray, qRT-PCR, fluorescence microscopy, and an in vitro lung aggregate culture.Affymetrix microarray revealed Wnt signaling to play a crucial role in the TD process. Wnt7a was identified as a ligand regulating the AT1 marker, Aquaporin 5 (AQP5). Artificial Neural Network (ANN) analysis of the Affymetrix data exposed ITGAV: Integrin alpha V (ITGAV), thrombospondin 1 (THBS1) and epithelial membrane protein 2 (EMP2) as Wnt signaling targets.Wnt signaling targets that can serve as potential alveolar epithelial repair targets in future therapies of the gas exchange surface after injury. As ITGAV is significantly increases during TD and is regulated by Wnt signaling, ITGAV might be a potential target to speed up the alveolar healing process.
LA  - English
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Elhusseiny, Mohamed Mahmoud Abdelwahab
AU  - Pál, Szilárd
AU  - Kvell, Krisztián
AU  - Sárosi, Veronika
AU  - Bay, Péter
AU  - Rue, R
AU  - Krymskaya, V
AU  - McPhail, D
AU  - Porter, A
AU  - Pongrácz, Judit
TI  - Mitochondrial dysfunction is a key determinant of the rare disease lymphangioleiomyomatosis and provides a novel therapeutic target.
JF  - ONCOGENE
J2  - ONCOGENE
VL  - 38
ET  - 0
PY  - 2019
IS  - 16
SP  - 3093
EP  - 3101
PG  - 9
SN  - 0950-9232
DO  - 10.1038/s41388-018-0625-1
UR  - https://m2.mtmt.hu/api/publication/30362166
ID  - 30362166
N1  - Funding Agency and Grant Number: European UnionEuropean Commission; State of Hungary - European Social Fund [TAMOP-4.2.4, A/2-11/1-2012-0001]
            Funding text: JEP was supported by the European Union and the State of Hungary, co-financed by the European Social Fund in the framework of TAMOP-4.2.4.A/2-11/1-2012-0001 "National Excellence Program".
AB  - Lymphangioleiomyomatosis (LAM) is a rare and progressive systemic disease affecting mainly young women of childbearing age. A deterioration in lung function is driven by neoplastic growth of atypical smooth muscle-like LAM cells in the pulmonary interstitial space that leads to cystic lung destruction and spontaneous pneumothoraces. Therapeutic options for preventing disease progression are limited and often end with lung transplantation temporarily delaying an inevitable decline. To identify new therapeutic strategies for this crippling orphan disease, we have performed array based and metabolic molecular analysis on patient-derived cell lines. Our results point to the conclusion that mitochondrial biogenesis and mitochondrial dysfunction in LAM cells provide a novel target for treatment.
LA  - English
DB  - MTMT
ER  - 

TY  - GEN
AU  - Salem, Ala'
AU  - F., Gosi
AU  - Nagy, Sándor
AU  - Pál, Szilárd
AU  - Széchenyi, Aleksandar
TI  - Nano-sized anti-tuberculosis multi-drug co-crystals
PY  - 2019
UR  - https://m2.mtmt.hu/api/publication/30882361
ID  - 30882361
LA  - English
DB  - MTMT
ER  - 

TY  - GEN
AU  - Ferenczi, Krisztina
AU  - Vörös-Horváth, Barbara
AU  - Kása, Péter
AU  - Nagy, Sándor
AU  - Széchenyi, Aleksandar
AU  - Pál, Szilárd
AU  - Hódi, Klára
TI  - A nanonizálás hatása a keményítőszemcsék dezintegráns hatására
PY  - 2019
UR  - https://m2.mtmt.hu/api/publication/30882388
ID  - 30882388
LA  - Hungarian
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Garai, Kitti
AU  - Ádám, Zoltán Mihály
AU  - Herczeg, Róbert
AU  - Kátai, Emese
AU  - Nagy, Tamás
AU  - Pál, Szilárd
AU  - Gyenesei, Attila
AU  - Pongrácz, Judit
AU  - Wilhelm, Márta
AU  - Kvell, Krisztián
TI  - Artificial Neural Network Correlation and Biostatistics Evaluation of Physiological and Molecular Parameters in Healthy Young Individuals Performing Regular Exercise
JF  - FRONTIERS IN PHYSIOLOGY
J2  - FRONT PHYSIOL
VL  - 10
PY  - 2019
PG  - 11
SN  - 1664-042X
DO  - 10.3389/fphys.2019.01242
UR  - https://m2.mtmt.hu/api/publication/30864198
ID  - 30864198
N1  - Funding Agency and Grant Number: Hungarian Academy of SciencesHungarian Academy of Sciences; Bolyai+ 2018/2019 (new national excellence program of the ministry of human capacities) [UNKP-18-4 2018/2019]; new national excellence program of the ministry of human capacities [UNKP-18-3-I 2018/2019];  [PTE AOK KA-2016-16];  [EFOP-3.6.1-16-2016-00004];  [GINOP-2.3.2.-15-2016-00047]
            Funding text: Scientific research support was provided by PTE AOK KA-2016-16, PTE Pharmaceutical Talent Center program, Janos Bolyai Scholarship of the Hungarian Academy of Sciences and Bolyai+ 2018/2019 (UNKP-18-4 2018/2019 new national excellence program of the ministry of human capacities) to KK and GINOP-2.3.2.-15-2016-00047 to MW. This work was also supported by the EFOP-3.6.1-16-2016-00004 to KK and JP; and the UNKP-18-3-I 2018/2019 new national excellence program of the ministry of human capacities to KG and ZA.
LA  - English
DB  - MTMT
ER  -